Phase 3 Tuberculosis Trial, Recruiting NCT04975178 Sponsor: Biofabri, S.L Condition: Tuberculosis
Back to Tuberculosis

Phase 3 Tuberculosis Trial, Recruiting

NCT04975178
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The baby must be male or female and enrolled within the first seven days after birth.
  • The mother must give written permission for her baby to take part, including allowing access to her own and her baby's medical records.
  • The family must be willing and able to attend follow-up appointments and take part in all study activities.
  • The baby must have been considered healthy during pregnancy and at birth, based on medical history and a physical check-up.
  • The baby must have weighed at least 2,450 grams (about 5.4 pounds) at birth.
  • The baby must have received an Apgar score (a quick health check done at birth) of 7 or higher at 5 minutes after birth.
  • A recent HIV test result for the mother must be on record — if she does not have HIV, the test must have been done within 30 days before or 7 days after delivery; if she does have HIV, she must be on HIV treatment with a very low level of virus in her blood.
  • The baby must have been born at or after 37 weeks of pregnancy (full term).
  • The mother must not have taken part in any clinical trial in the three months before the baby's birth.
  • The mother must never have taken part in a tuberculosis (TB) vaccine trial before.
  • The baby must not be enrolled in any other clinical trials at the same time.

Who may not be able to join:

  • The baby has already received a BCG vaccine (a vaccine commonly given at birth to protect against TB) before joining the trial.
  • There were serious complications during or after pregnancy that could affect the baby's health.
  • There is a skin problem, bruise, or birthmark at the spot on the body where the injection would be given.
  • The mother's HIV test result is not available.
  • The baby was exposed to HIV and their own HIV test result came back positive or is not yet available.
  • The mother had tuberculosis (TB) during pregnancy.
  • Anyone in the baby's home has TB and has not yet finished their TB treatment.
  • The baby shows signs of a serious blood infection (neonatal sepsis).
  • The baby was born with a severe physical abnormality.
  • The baby has any signs of a serious illness or condition that, in the doctor's judgement, could affect how the trial results are measured (mild newborn jaundice on its own does not count as a reason to exclude the baby).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mark Hatherill, University of Cape Town, Faculty of Health Sciences

Phone: +34 986 33 04 00

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Biofabri, S.L
Registry
ClinicalTrials.gov
Start date
17 October 2022
Est. completion
1 February 2029

Where this trial is recruiting

🇿🇦 South Africa

Primary endpoints

To demonstrate efficacy in terms of incidence of MTBVAC against TB disease in healthy HU and HEU newborns compared to BCG

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov